It was found that high expression of the stemness markers PROM1 or SOX2 significantly correlates with high levels of several glycolytic enzymes (GAPDH, LDHB and PFKP) in GBM patient tumors (Fig. 2d). The gene discussed is GAPDH; the disease is glioblastoma.